38
Participants
Start Date
November 14, 2019
Primary Completion Date
April 3, 2023
Study Completion Date
October 30, 2023
Shingrix®
A zoster vaccine recombinant, adjuvanted, recently approved by the FDA for prevention of herpes zoster (shingles) in adults aged 50 years and older. It is given in two doses (0.5 mL each): at 0 and 2 to 6 months.
The Hope Clinic, Decatur
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Emory University
OTHER